Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.
Grant
Overview
Affiliation
Overview
Awarded By
University of Chicago ^
Total Award Amount
102500.00
Direct Costs
78846.00
Sponsor Award Id
Affiliation
Contributor
Erica Stringer-Reasor M.D.
Principal Investigator
Gabrielle Rocque M.D.
Investigator